Re-investigation of the circumsporozoite protein-based induction of sterile immunity against Plasmodium berghei infection

Vaccine

Volumn 14, Issue 8, 1996, Pages 828-836

  Reed, Robb C ^a,c   Louis Wileman, Valerie ^a,c   Wells, R Lance ^b   Verheul, Andre F M ^c   Hunter, Robert L ^a   Lal, Altaf A ^c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c NATL CENTER FOR INFECTIOUS DISEASES   (United States)

Author keywords

Circumsporozoite protein; Malaria; Peptide carrier conjugate; Plasmodium berghei; Sporozoite; Vaccine

Indexed keywords

MALARIA VACCINE; PARASITE ANTIGEN;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; IMMUNITY; MALARIA; MOUSE; NONHUMAN; PLASMODIUM BERGHEI; PRIORITY JOURNAL; SPOROZOITE; VACCINATION;

EID: 0030175930     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0264-410X(95)00175-Z     Document Type: Article

References (27)

1. 1 Nussenzweig, V. and Nussenzweig, R.S. Rationale for the development of an engineered sporozoite malaria vaccine. Adv. Immunol. 1989, 45, 283
2. 2 Tam, J.P., Clavijo, P., Lu, Y.A., Nussenzweig, V., Nussenzweig, R.S. and Zavala, F. Incorporation of T and B epitopes of the circumsporozoite protein in a chemically defined synthetic vaccine against malaria. J. Exp. Med. 1990, 171, 299
3. 3 Lal, A.A. et al. In vivo testing of subunit vaccine against malaria sporozoites using a rodent system. Proc. Natl Acad. Sci. USA 1987, 84, 8647-8651
4. 4 Egan, J.E. et al. Efficacy of murine malaria sporozoite vaccine: Implications for human vaccine development. Science 1987, 236, 453-456
5. 5 Zavala, F. et al. Synthetic peptide vaccine confers protection against murine malaria. J. Exp. Med. 1987, 166, 1591
6. 6 Hunter, R.L., Strickland, F. and Kezdy, F. Studies on the adjuvant activity of nonionic block polymer surfactants. I. The role of hydrophile-lipophile balance. J. Immunol. 1981, 127, 1244-1250
7. 7 Hunter, R.L. and Bennett, B. Glycolipids in the pathogenesis of tuberculosis: studies on the relationship between the physiochemical properties and biologic activities of synthetic analogs of trehalose 6-6′ dimycolate. Proceedings of 19th Joint US-Japan Leprosy and Tuberculosis Conference, 1984, 263-278
8. 8 Hunter, R.L. and Bennett, B. The adjuvant activity of nonionic block polymer surfactants. III. Characterization of selected biologically active surfaces. Scand. J. Immunol. 1986, 23, 287-300
9. 9 Hunter, R.L., Olsen, M.R. and Buynitzky, S. Adjuvant activity of nonionic block copolymers. IV. Effect of molecular weight and formulation on titer and isotype of antibody. Vaccine 1991, 9, 250-256
10. 10 Kalish, M.L., Check, I.J. and Hunter, R.L. Murine IgG isotype responses to the Plasmodium cynornolgi circumsporozoite protein (NAGG)5. I. Effects of carrier, copolymer adjuvants, and nontoxic LPS on isotype selection. J. Immunol. 1991, 146, 3583-3590
11. 11 Millet, P., Kalish, M.L., Olsen, M., Grady, K.K., Collins, W.E. and Hunter, R.L. Role of adjuvant formulations based on copolymers in the design of a malaria peptide vaccine. Am. J. Trop. Med. Hyg. 1991, 45 (Suppl.), 286
12. 12 tenHagen, T.L.M., Sulzer, A.J., Kidd, M., Lal, A.A. and Hunter, R.L. The role of adjuvants in the modulation of antibody specificity and induction of protection by whole blood-stage Plasmodium yoelii vaccines. J. Immunol. 1993, 151, 7077-7085
13. 13 Wang, R. et al. Protection against Plasmodium yoelii by CS protein multiple antigen peptide-induced polyclonal antibodies. Am. J. Trop. Med. Hyg. 1993, 49, 317
14. 14 Pacheco, N.D., Strome, C.P.A., Mitchell, F., Bawden, M.P. and Beaudoin, R.L. Rapid, large-scale isolation of Plasmodium berghei sporozoites from infected mosquitoes. J. Parasitol. 1979, 65, 414-417
15. 15 Rougon, G., Ceard, B., Van Rietschoten, J., Jordan, B. and Barbet, L. Induction with a synthetic peptide of antibodies to HLA class I C-terminal intracytoplasmic region. Mol. Immunol. 1984, 21, 461
16. 16 Schmitz, K.E. An Introduction to Dynamic Light Scattering. Academic Press, Boston, MA, 1990
17. 17 Takayama, K., Olsen, M., Datta, P. and Hunter, R.L. Adjuvant activity of nonionic block copolymers V. Modulation of antibody isotype by lipopolysaccharides Lipid A and precursors. Vaccine 1991, 9, 257-265
18. 18 Rickman, L.S. et al. Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A, and squalane in malaria circumsporozoite protein vaccine. Lancet 1991, 337, 998
19. 19 Ak, M. et al. Monoclonal antibodies of three different immunoglobulin G isotype produced by immunization with a synthetic peptide or native protein protect mice against challenge with Plasmodium yoelii sporozoite. Infect. Immun. 1993, 61, 2493-2497
20. 20 Sulzer, A.J. and Wilson, M. The fluorescent antibody test for malaria. Crit. Rev. Clin. Lab. Sci. 1971, 52, 273
21. 21 Oaks, S.C., Mitchell, V.S., Pearson, G.W. and Carpenter, C.C. (Eds). Malaria, Obstacles and Opportunities. National Academy Press, Washington DC, 1991, p. 309
22. 22 Hui, G.S. et al. Influence of adjuvants on the antibody specificity to the Plasmodium falciparum major merozoite surface protein gp1951. J. Immunol. 1991, 147, 3935-3941
23. 23 Mattei, D. et al. Cross-reactive antigenic determinants present on different Plasmodium falciparum blood-stage antigens. Parasite Immunol. 1989, 11, 15-30
24. 24 Hope, I., Hall, R., Simmons, D., Hyde, J. and Scaife, J. Evidence of immunological cross-reaction between sporozoites and blood stages of a human malaria parasite. Nature 1984, 308, 191-194
25. 25 Que, J.U. et al. Effect of carrier selection on immunogenicity of protein conjugate vaccines against Plasmodium falciparum circurnsporozoite. Infect. Immun. 1988, 56, 2645
26. 26 Cruse, J.M. and Lewis, R.E.Jr Conjugate vaccines. Contrib. Microbiol. Immunol. 1989, 10, 48-114
27. 27 Briand, J.P., Muller, S. and Van Regenmortel, M.H.V. Synthetic peptides as antigens: pitfalls of conjugation methods. J. Immunol. Meth. 1985, 78, 59-69